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I n t r o d u c t i o n.  Ewing’s family tumours often show characteristic chromosomal abnormalities: t(11;22)(q24;q12) and
t(21;22)(q22;q12) with a formation of EWS/FLI-1 and EWS/ERG fusion genes.
A i m  o f  t h e  s t u d y.  The presence of specific fusion genes in Ewing family tumours: EWS/FLI-1 and EWS/ERG was
assessed in order to establish their clinical role in children with these tumours.
M a t e r i a l  a n d  m e t h o d s.  46 patients (28 boys and 18 girls) entered this multicenter study. Tissue samples were collected
and PNET or EES diagnosis was retrospectively confirmed by two independent pathologists. Institutional ethical board
consent was obtained for all participating institutions. Patient age ranged between 9 and 207 months (mean 114±62
months). The extent of the disease was graded according to the clinical staging system with the following distribution: 5 children
with stage II, 30 with stage III and 11 with stage IV disease having distant metastases. RNA was obtained both from fresh-
frozen and paraffin embedded tissue biopsy samples. RT-PCR specific primers were used on isolated tumour RNA, followed
by electrophoresis for screening of two targeted translocations.
R e s u l t s.  Fusion genes were detected in 31 (67%) tumour samples. The most common fusion gene was EWS/FLI-1 7-6,
which was detected in 18 patients. We observed no significant differences between patients with different mutation variants
according to age, sex, tumour size and localisation, disease stage, regional lymph node involvement, metastasis event-free and
overall survival.
C o n c l u s i o n s.  Because of a considerable heterogeneity of genetic changes observed in Ewing’s family tumours, results in
this group of patients were not fully clear. We were not able to confirm if any mutation is connected with better or poorer
prognosis, or with any of the studied clinical parameters.
ObecnoÊç genów fuzyjnych EWS/FLI-1 i EWS/ERG w guzach rodziny Ewinga u dzieci i m∏odzie˝y
W p r o w a d z e n i e.  Guzy z rodziny Ewinga cz´sto demonstrujà charakterystyczne translokacje t(11;22)(q24;q12) oraz
t(21;22)(q22;q12), z tworzeniem genów fuzyjnych, odpowiednio EWS/FLI-1 i EWS/ERG.
C e l e m  b a d a n i a  by∏a ocena obecnoÊci genów fuzyjnych EWS/FLI-1 i EWS/ERG w guzach z rodziny Ewinga celem
okreÊlenia ich klinicznego znaczenia wÊród dzieci z tymi nowotworami.
M a t e r i a ∏  i m e t o d y.  Do badania zakwalifikowano 46 pacjentów (28 ch∏opców i 18 dziewczynek). Od ka˝dego pacjenta
z rozpoznanym PNET lub EES uzyskano fragment guza do badania. Badanie zosta∏o zaaprobowane przez komisje etyczne
wszystkich oÊrodków bioràcych udzia∏ w analizie. Wiek pacjentów waha∏ si´ od 9 do 207 miesi´cy (Êrednio 114±62 miesi´cy).
Stopieƒ zaawansowania choroby okreÊlono na podstawie kryteriów klinicznych z nast´pujàcym rozk∏adem: 5 dzieci w stadium
II, 30 w stadium III oraz 11 w stadium IV choroby z obecnoÊcià przerzutów odleg∏ych. RNA uzyskiwano zarówno z materia∏u
Êwie˝o zamro˝onego, jak równie˝ z materia∏u utrwalonego w parafinie. Uzyskane RNA amplifikowano w obecnoÊci
specyficznych primerów dla poszukiwanych translokacji w reakcji RT-PCR, a uzyskane produkty rozdzielano za pomocà
elektroforezy ˝elowej.
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Introduction
Primitive peripheral neuroectodermal tumour (PNET)
and extraosseous Ewing’s sarcoma (EES) account for
approximately 13% of soft tissue malignant neoplasms
in children and adolescents [1, 2]. Both tumours are
predominantly localised within pelvis (45%), thorax wall
(including Askin’s tumours – 34%) and in the para-
vertebral region (12%) (2). Metastases are most common
to the lungs (38%), the bones (31%), and to the bone
marrow (12%) (2). Although for many years both
tumours were regarded as separate entities, recent
findings of typical cytogenetic abnormalities have allowed
to classify both these tumours together with the classic
Ewing’s sarcoma of bones to the family of Ewing’s
tumours. The most frequent and characteristic feature
of the Ewing’s family tumours chromosomal abnormality
is translocation t(11;22)(q24;q12) with a formation of the
EWS/FLI-1 fusion gene. As the fusion gene could be
formed from different exons, several types of EWS/FLI-1
exist. Less common are translocations t(21;22)(q22;q12)
(EWS/ERG fusion gene), t(7;22)(p22;q12) (EWS/ETV-1
fusion gene), and t(17;22)(q12;q12) (EWS/EAF-1 fusion
gene) [3, 4].
In 1991 a new classification of PNET and EES
tumours was suggested [5]. According to this classifi-
cation, tumours which demonstrate at least two neuronal
markers (e.g. NSE, S-100 protein, HNK-1, neurofilaments
or GPAP) and/or create Homer-Wright rosettes can be
classified as PNET; and tumours which present none or
only one neuronal marker can be classified as Ewing’s
sarcoma [5]. However, until the final consensus is not
ready, it is postulated to handle all these tumours together
in scientific analyses.
The normal function of the EWS gene is unclear,
but it is ubiquitously expressed in cells and contains an
RNA-binding domain [6]. The FLI-1 gene is a member of
the ETS family of proto-oncogenes. The gene contains
a DNA-binding domain and functions as a transcriptional
activator [7]. The fusion transcript in EES and PNET
includes the promoter region of the EWS gene and
a protein-protein interaction domain [8, 9]. The RNA-
binding domain of the EWS gene is lost and replaced by
the DNA-binding domain of the FLI-1 gene via a hinge
region of variable length, depending on the breakpoints in
the two genes [9]. The fusion protein shows increased
transcriptional activity in vitro compared with the normal
FLI-1 gene and can induce neoplastic transformation in
fibroblasts [9]. The other genes, which were proved to
form fusion genes with EWS gene in Ewing family
tumours, belong all to the ETS family of transcription
factors. The ERG gene is highly homologous to the 
FLI-1 gene and is believed to have similar activity [10].
The EAF-1 gene encodes adenovirus E1A enhancer
binding protein, which activates matalloproteinase genes
[9].
As the fusion genes seem to play an important role
in carcinogenesis of Ewing’s family tumours, it seemed
reasonable to compare the clinical behaviour of tumours
with different variants of translocations.
Material
Tissue samples were retrospectively obtained from 50 patients
with PNET or EES diagnosed in different institutions. Four
patients were excluded from further analysis as the tissue
samples were negative (absence of GAPDH gene sequences)
suggesting poor quality of the isolated RNA. The final evaluation
thus included 46 patients: 33 (71.7%) with PNET and 13 (28.3%)
with EES. There were 28 (60.9%) boys and 18 (39.1%) girls,
aged between 9 and 207 months (mean: 114±62 months, median
value 126 months). The morphologic diagnosis of PNET or EES
was confirmed by two independent referent pathologists. Clinical
staging on presentation revealed 5 patients (10.9%) having stage
II disease, 30 stage III (65.2%) and 11 (23.9%) with stage IV
with distant metastases. Regional lymph node involvement was
found in 6 children (13%). Nine (19.6%) primary tumours were
limited to the organ or tissue of origin (stage T1 according to the
TNM classification), while in 37 (80.4%) patients the tumour
infiltrated the neighbouring organs (stage T2). Primary tumour
size below 5 cm occurred in 9 (19.6%) children, and over 5 cm –
in 37 children (80.4%). The primary tumours were localised
within the trunk in 20 cases (43.4%), on the extremities in 13
cases (28.3%), on the head/neck in 10 cases (21.7%), and in the
pelvis in 3 cases (6.5%) children. In spread tumours, the most
common sites of metastases were the lungs – 6 patients, the
bone marrow – 2 patients, the liver – 2 patients, the bones –
2 patients, non-regional lymph nodes – 2 patients, the pleura –
2 patients, and the skin – 1 patient. The site of metastases was
not precisely indicated in 1 child.
All PNET/EES children underwent multimodal chemo-
therapy, combination radiotherapy and surgery. Treatment
protocols used were: the CWS-91 protocol [11] for 10 children
(21.7%), the EICESS-92 protocol for 3 children (6.5%) and the
CWS-96 protocol [12] for 32 children (71.7%). The median
follow up for all patients was 26.5 months – 39 months for
surviving patients (n=25).
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W y n i k i.  ObecnoÊç genów fuzyjnych stwierdzono w przypadku 31 (67%) nowotworów. Najcz´stszym genem fuzyjnym by∏
EWS/FLI-1 7-6, który wykryto u 18 pacjentów. Nie obserwowano istotnych ró˝nic pomi´dzy pacjentami z ró˝nymi wariantami
mutacji odnoÊnie wieku, p∏ci, wielkoÊci i lokalizacji guza, stadium choroby, zaj´cia regionalnych w´z∏ów ch∏onnych, obecnoÊci
przerzutów, prze˝yciem wolnym od choroby i prze˝yciem ca∏kowitym.
W n i o s k i.  Ze wzgl´du na du˝à ró˝norodnoÊç zmian genetycznych, stwierdzanych w guzach z rodziny Ewinga, uzyskane wyniki
nie sà w pe∏ni jednoznaczne. Nie stwierdzono, aby którykolwiek wariant mutacji zwiàzany by∏ z gorszym rokowaniem, lub
z którymkolwiek analizowanym parametrem klinicznym.
Key words: PNET, Ewing sarcoma, fusion genes, children
S∏owa kluczowe: PNET, guz Ewinga, geny fuzyjne, dzieci
Methods
Samples for RNA investigation according to the method
modified by Stegmaier et al. [13] were obtained both from fresh-
frozen and paraffin embedded tissue biopsies. All tissue samples
were checked by two reference pathologists in order to confirm
that the evaluated material is representative for RMA.
R N A  i s o l a t i o n  f r o m  p a r a f f i n  e m b e d d e d
t i s s u e  s a m p l e s
Several 4-5 µm thick sections were prepared from each sample.
All paraffin sections put into microtubes underwent xylene
deparaffinisation (15 min. at 37°C). The samples were than
washed out twice with 100% ethanol. After evaporation at room
temperature sediments were diluted in a buffer consisting of 20
mM Tris-HCl (pH 7.5), 20 mM EDTA, 1% SDS (sodium dodecyl
sulfate) and 0.08% Proteinase K solution (Roche, No 1 964
364). The total RNA content was obtained after cell lysis (12
hours at 56°C) with Trizol Reagent (Invitrogen No 15596-018)
according to the instruction supplied by the manufacturer. The
obtained sediment was rinsed out with 75% ethanol, dried out at
room temperature and diluted once more in H2ODEPC. The
obtained RNA was treated with 10 U DNase (RNase–free,
Roche No 776785) (15 min., 25°C) in the presence of Rnasin
(Roche, 75 U). For DNase inactivation the Trizol Reagent was
used for a second time. The precipitated RNA was diluted in
H2ODEPC and stored at –70°C until investigation.
R N A  i s o l a t i o n  f r o m  f r e s h - f r o z e n  m a t e r i a l
The fresh-frozen samples were homogenized with the Miccra D-
8 homogenizator (Art-moderne LaBortechnik). Each sample
was than treated with Trizol Reagent in the same way as was
described above except for the DNase procedure.
RT- P C R
RNA concentration was measured with the spectrophotometer
(λ=260nm – Smartspec™ 3000, BIORAD). For cDNA synthesis
we used 1 µg of RNA obtained from each sample. The
transcription was performed using a reverse transcriptase
provided in a 1st Strand cDNA Synthesis Kit for RT-PCR (AMV,
Roche No 1483188) in the presence of 5 mM MgCl2 and primers
(dT15-primer for fresh-frozen material, and dN6–primer for
RNA obtained from paraffin-embedded samples) according to
the manufacturer’s instruction. The quality of the isolated RNA
was checked by amplification of a 495bp sample for the human
beta-actin in a case of fresh-frozen tissues (primers sequence
according to Stegmaier, GenBank accession, No M 10277) or
a 226bp sample for the human 3-phosphoglyceraldehyde
dehydrogenase (GAPDH – primers sequence according to PE
Biosystem, TaqMan Gold RT-PCR Kit, GenBank J04038) in
a case of paraffin-embedded samples. The single strain of cDNA
obtained in the RT-PCR was amplified in PCR using specific
primers for EWS/FLI-1 7–6, EWS/FLI-1 7-5, EWS/FLI-1 7-8,
EWS/FLI-1 10-5, EWS/FLI-1 10-6 and EWS/ERG 7-6 fusion
genes. PCR was performed with an Ampli Taq Gold®Taq DNA
polimerase (Applied Biosestem) to a final concentration of 1.5
mM MgCl2 and each primer at 0.5 µM. In the case of fresh-
frozen samples 35 cycles of PCR, and in the case of paraffin-
embedded tissue samples 60 PCR cycles were performed. The
RT-PCR products underwent electrophoresis in a 1.5% agarose
gel with TAE buffer (0.04 mM TRIS-acetate, 0.001 M EDTA, 0.5
µg/µl etidine bromide) (Figure 1).
In each case a positive tumour sample (with previously
confirmed translocation) and negative control (evaluated tissue
sample, however, without primers added) were added. Each
step of the procedure (tissue preparation, RNA isolation, PCR
amplification and electrophoresis) was performed in a separate
room in order to avoid contamination.
S t a t i s t i c a l  a n a l y s i s
The possible differences between the evaluated groups of
patients were assessed with the Student’s t-test in case of
parametric values, or with the χ2 test with appropriate
modifications in case on nonparametric values. The Kaplan-
Meier overall survival (OS) was calculated from the date of the
start of therapy until the latest follow-up or death from any
cause, the Kaplan-Meier event-free survival (EFS) – from the
date of the start of therapy until the time of treatment failure.
Failure was defined as relapse or death from any cause. The
differences between the curves were estimated by the log rank
test and p-values less than 0.05 were considered as significant.
Results
Fusion genes were detected in 31 (67%) tumour samples
(Figure 1 and 2). Eighteen (39%) tumours presented
EWS/FLI-1 7-6 fusion gene, 6 (13%) EWS/FLI-1 7-5
fusion gene, 3 (7%) EWS/FLI-1 10-5 fusion gene, 2 (4%)
EWS/FLI-1 10-5 fusion gene, 1 (2%) EWS/FLI-1 7-8
fusion gene, and 1 (2%) EWS/ERG fusion gene
(Figure 3). The remaining 15 tissue samples did not show
any of the assessed genetic abnormalities.
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a)
b)
165 bp ews-fli1 7-5
100 bp ews-fli1 7-6
165 bp ews-fli1 7-5
100 bp ews-fli1 7-6
different exon fusions:
226 bp gapdh
breakpoint
M M– + 2 3 4 5 6 7 8 9 10 11 12 + –1
–M – M+ + 2 3 4 5 6 7 8 9 10 11 12 + +1
ews exon 7 fli1 exon 6
ews exon 7 fli1 exon 5 fli1 exon 6
7+57+6
Figure 1. Agarose gel electrophoresis of RT-PCR products from Ewing’s
sarcoma/PNET patients 1-12. (M = size marker (100 bp fragment
ladder). Positive and negative PCR controls as indicated).
a) EWS/FLI-1 fragments 100 bp (exon fusion EWS 7 – FLI1 6) and
165 bp (exon fusion EWS 7 – FLI-1 5). Forward primer EWS-794-814,
reverse primer FLI-1-854-834: Patients 1-3, 5, 10 and 11 show 100 bp
fragments. Patient no 6 shows 165 bp fragment. For patients 4, 7-9 and 12
no EWS/FLI-1 products were amplified with these primers.
b) GAPDH control fragments 226 bp. For patients 3, 8 and 12 no
GAPDH fragments were amplified, indicating poor quality of RNA.
Primers according to Perkin Elmer / Applied Biosystems (‘TaqMan®
Gold RT-PCR Kit’ mannual)
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Table I. Clinical characteristics of tumours with different fusion genes
Fusion genes
Characteristics EWS/FLI-1 7-5 EWS/FLI-1 7-6 EWS/FLI-1 7-8 EWS/FLI-1 10-5 EWS/FLI-1 10-6 EWS/ERG No fusion genes
n=6 n=18 n=1 n=2 n=3 n=1 n=15
Gender:
– male 4 (67%) 8 (44%) 1 (100%) 1 (50%) 2 (67%) 1 (100%) 11 (73%)
– female 2 (33%) 10 (56%) – 1 (50%) 1 (33%) – 4 (27%)
Histology:
– EES 4 (67%) 5 (28%) – 1 (50%) – – 3 (20%)
– PNET 2 (33%) 13 (72%) 1 (100%) 1 (50%) 3 (100%) 1 (100%) 12 (80%)
T-stage:
– T1 (non-invasive) 1 (17%) 4 (22%) – 1 (50%) 1 (33%) – 2 (13%)
– T2 (invasive) 5 (83%) 14 (78%) 1 (100%) 1 (50%) 2 (67%) 1 (100%) 13 (87%)
Tumour size:
– <5 cm 2 (33%) 3 (17%) – – 1 (33%) – 3 (20%)
– ≥5 cm 4 (67%) 15 (83%) 1 (100%) 2 2 (67%) 1 (100%) 12 (80%)
Localisation
– Head/neck 1 (17%) 4 (22%) 1 (100%) – – – 4 (27%)
– Trunk 2 (33%) 9 (50%) – 2 (100%) 1 (33%) – 6 (40%)
– Pelvis 1 (17%) – – – – 1 (100%) 1 (6%)
– Extremities 2 (33%) 5 (28%) – – 2 (67%) – 4 (27%)
Regional lymph node 
involvement
– Yes – 2 (11%) – – – – 4 (27%)
– No 6 (100%) 16 (89%) 1 (100%) 2 (100%) 3 (100%) 1 (100%) 11 (73%)
Metastases:
– Yes 1 (17%) 2 (11%) – 1 (50%) – 1 (100%) 6 (40%)
– No 5 (83%) 16 (89%) 1 (100%) 1 (50%) 3 (100%) – 9 (60%)
Disease stage
– II – 2 (11%) – – – – 3 (20%)
– III 5 (83%) 14 (78%) 1 (100%) 1 (50%) 3 (100%) – 6 (40%)
– IV 1 (17%) 2 (11%) – 1 (50%) – 1 (100%) 6 (40%)
Metastases localisation:
– Lungs – 1 – – – 1 4
– Bone marrow – 1 – 1 – – –
– Liver – – – – – – 2
– Non-regional lymph nodes 1 1 – – – – –
– Bones – – – 1 – – 1
– Pleura 1 1 – – – – –
– Skin – 1 – – – – –
Table II. Treatment results of patients suffering from peripheral primitive neuroectodermal tumour or extraosseous Ewing’s sarcoma according 
to the presence of different fusion genes
Fusion genes
Clinical outcome EWS/FLI-1 7-5 EWS/FLI-1 7-6 EWS/FLI-1 7-8 EWS/FLI-110-5 EWS/FLI-1 10-6 EWS/ERG No fusion genes
n=6 n=18 n=1 n=2 n=3 n=1 n=15
Alive 3 (50%) 11 (61%) 1 (100%) 2 (100%) 2 (33%) – 6 (40%)
Dead 3 (50%) 7 (39%) – – 1 (67%) 1 (100%) 9 (60%)
Response to chemotherapy
(only stage III and IV):
Regression of tumour >2/3 1 (17%) 7 (44%) 1 (100%) 1 (50%) 2 (67%) – 8 (67%)
Regression of tumour <2/3 5 (83%) 9 (56%) – 1 (50%) 1 (33%) 1 (100%) 4 (33%)
Disease status:
Alive in 1st CR 1 (17%) 8 (44%) 1 (100%) 1 (50%) 2 (67%) – 5 (33%)
Progression 2 (33%) 2 (11%) – 1 (50%) – 1 (100%) 4 (27%)
Relapse 3 (50%) 8 (44%) – – 1 (33%) – 6 (40%)
– local 1 (17%) 5 (28%) – – – – 2 (13%)
– metastatic 1 (17%) 2 (11%) – – – – 2 (13%)
– mixed 1 (17%) 1 (6%) – – 1 (33%) – 2 (13%)
Second CR 1* (17%) – – – – – –
CR – complete remission
* Second CR was achieved in one patient with local relapse
The patients’ clinical characteristics depending on
the stated fusion gene are listed in Table I. We did not
find any relationships between any of the specific type
of translocations and patients’ age, gender, tumours’ size,
stage and localisation. It seemed that in the case of
tumours with translocations regional lymph node
involvement was less frequent than in the case of tumours
without translocations (2/31 and 4/15, respectively;
p=0.08) as were distant metastases (5/31 and 6/15,
respectively; p=0.08). The results of treatment are shown
in Table II. As the group of patients presenting tumours
with specific fusion genes was very heterogenous, we did
not find any significant differences concerning the
outcome among the assessed subgroups. We noticed that
patients who presented with translocations, had a slightly
better overall survival as compared to patients without
translocations (estimated 5-year OS 0.53 and 0.27,
respectively), but the difference was not statistically
significant (p=0.15; Figure 4). Similar results were
achieved for event free survival: estimated 5-year EFS
0.42 and 0.29, respectively; p=0.39.
Discussion
The precise histological diagnosis of soft tissue tumours is
essential for the selection of the most effective anti-
tumour therapy. Several immunohistochemical markers,
as well as electron microscopy, have proven their efficacy
in the differential diagnosis of different malignancies in
children and adolescents. However, even with the help
of electron microscopy and immunohistochemistry, the
precise diagnosis can still be hard to establish in some
patients with very low tumour differentiation [14].
Moreover, the increased use of guided-needle biopsy
methods has reduced the availability of adequate tissue
volume for optimal histological studies. Therefore, it
seems that the detection of specific fusion genes,
characteristic for different sarcomas, could be very helpful
and important in the differential diagnosis of children
with soft tissue neoplasms. We have shown that the
evaluation of fusion genes is also possible to perform in
archival paraffin-embedded tissue samples. We detected
the characteristic translocations for Ewing’s family
tumours in 67% malignancies.
However, still little is known concerning the
significant clinical differences between Ewing’s sarcomas
with different fusion genes. Ginsberg et al., analysing 136
patients with Ewing’s sarcoma, did not find any significant
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Figure 2. Agarose gel electrophoresis of RT-PCR products from Ewing’s
sarcoma/PNET patients 4, 7-9, 12. (M = size marker (100 bp fragment
ladder). Positive and negative PCR controls as indicated).
a) EWS/ERG fragments 100 bp (exon fusion EWS 7 – ERG 6). Forward
primer EWS-794-814, reverse primer ERG-652-628. Patient 4 positive.
b) EWS/FLI-1 fragments 178 bp (exon fusion EWS 10 – FLI-1 5), patient
7 positive; and 112 bp (exon fusion EWS 10 – FLI-1 6) patient 8 positive.
c) EWS/FLI-1 fragment 178 bp (exon fusion EWS 7 – FLI-1 8), 129 bp
(exon fusion EWS 7 – FLI-1 9; no positive control available) and 237 bp
(exon fusion EWS 7 – FLI1 7; no positive control available).
For patient 12 no EWS/FLI-1 or –ERG products were amplified with
these primer pairs
EWS/FLI-1 7-5
EWS/FLI-1 10-5
No translocation
EWS/FLI-1 7-6
EWS/FLI-1 10-6
EWS/FLI-1 7-8
EWS/ERG 7-6
33%
13%
39%
2%4%
7%
2%
Figure 3. Frequency of fusion genes among analysed tumours
Figure 4. Comparison of overall survival between patients with
tumours with and without fusion genes characteristic for tumours of
the Ewing’s family
clinical differences between tumours demonstrating
EWS/FLI-1 and EWS/ERG fusion genes according to age
at diagnosis, sex, metastasis at diagnosis, primary sites,
event-free survival and overall survival [15]. As in our
patient group only one tumour demonstrated EWS/ERG
fusion gene, we were not able to confirm these findings.
Some authors have demonstrated that the precise exon
composition of EWS/FLI-1 fusion transcripts was found to
be a prognostic indicator for Ewing’s sarcoma [16, 17].
For localized Ewing’s sarcoma, patients with tumours
that express the type 1 fusion, where exon 7 of EWS is
joined to exon 6 of FLI-1, have an improved overall
survival as compared to patients with tumours that
express non-type 1 EWS/FLI-1 fusions [16, 17]. Because of
a considerable heterogeneity of genetic changes observed
in Ewing’s family tumours, the results in this group of
patients were not fully clear. We were not able to confirm
whether any mutation related to better or poorer
prognosis. We could only state that patients with
EWS/FLI-1 7-6 had slightly better outcome than others
(data not shown), however, the observed differences were
not significant (p=0.6). This discrepancy could be
explained by the fact, that the previously mentioned
studies included all patients with Ewing’s family tumours,
with the predominance of Ewing‘s sarcoma of bones. In
our study we have investigated only these tumours, which
had primarily originated from soft tissue. It is possible
that soft tissue tumours could show different biological
properties than bone tumours.
The genetic analysis of paediatric neoplasms has
resulted in the identification of new genetic abnormalities
and in improved understanding of tumour origin and
progression. It is possible that these findings may allow to
develop new therapeutic strategies in the future, for
example the employment of anti-sense nucleotides
sequences, monoclonal antibodies against fusion proteins
or specific inhibitors of fusion proteins.
To summarise, proper pre-treatment stratification
of patients with soft tissue sarcomas allows to optimise
anti-tumour therapy. Despite the significant progress in
the therapy of soft tissue sarcomas it is still necessary to
search for new prognostic markers, which would lead to
a better classifications of patients according to their real
chance for successful therapy. Although the presence of
different fusion transcripts could have an impact on the
clinical course of Ewing’s tumours, further investigations
are necessary to clarify the exact importance of these
genetic abnormalities. However, as we have not observed
any significant relationship between the presence of
fusion genes and the clinical behaviour of the tumours, it
is possible, that molecular changes play only a minor part
in the determination of the clinical course of Ewing’s
sarcoma.
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